The antitrust agency paused its lawsuit against the pharmacy benefit manager while the two discuss a proposed consent agreement.

HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but these celebrations were tempered by insurers’ reluctance to cover its ...